T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Clinical trial NCT03318900 · COMPLETED

Trial details

NCT number: NCT03318900
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

COL6A3 Positive HLA-A*0201 Positive Cells Present PRAME Positive Recurrent Ovarian Carcinoma

Start date: 2018-09-04
Primary completion: 2023-12-20
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.